Today there are over 10,000 rare diseases affecting more than 30 million people in the U.S.1 Many of these disorders are life-threatening, and more than 90% do not have a U.S. FDA-approved treatment2. Novel gene therapies offer hope for improving the health of patients afflicted with these conditions. Securing clearance for these treatments is…
Expertise: Cell & Gene Therapy 38 results
Today there are over 10,000 rare diseases affecting more than 30 million people in the U.S.1 Many of these disorders are life-threatening, and more than 90% do not have a U.S. FDA-approved treatment2. Novel gene therapies offer hope for improving the health of patients afflicted with these conditions. Securing clearance for these treatments is…
Cell & Gene Therapy
Where Biomarkers and Gene Therapy Trials Intersect: Benefits Abound
We’re currently experiencing breakthrough times for clinical research in gene therapies. These complex treatments offer much-needed hope to more than 30 million U.S. patients affected by over 1000 rare diseases1, many of which are life-threatening and the vast majority of which have no available treatment. Gene therapy products must meet the same key regulatory…
Rare Disease
Daniel Zamfir, MBA
Cell & Gene Therapy
Kenneth Ndugga-Kabuye, M.D., FACMG
Cell & Gene Therapy
Greg Meyer
Cell & Gene Therapy
Jessica Merryfield
Cell & Gene Therapy
Olu Aloba, Ph.D.
Cell and Gene Therapy Expert Dr. Kenneth Ndugga-Kabuye to Lead Clinical Strategy With Collaboration From Operations, CMC and Regulatory Experts MORRISVILLE, N.C., April 17, 2023– Premier Research announced today the addition of Kenneth Ndugga-Kabuye, M.D., FACMG, as VP, Cell & Gene Therapy to the strategic Cell & Gene Therapy (CGT) Leadership Team. Ndugga-Kabuye joins experts…